A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

Exclusion Criteria

• •Medical history of confirmed deep venous thrombosis or arterial thromboembolism within 2 years of signing the informed consent form (ICF).
• •Risk factors for venous thromboembolism or arterial thrombosis, prothrombotic status.
• •Concomitant polymyositis or dermatomyositis or systemic sclerosis.
• •Active malignancy or history of malignancy, except in situ carcinoma of the cervix and cutaneous basal cell carcinoma.
• •Hepatitis B, hepatitis C, or human immunodeficiency virus infection.
• •More than one episode of herpes zoster and/or an opportunistic infection in the last 12 months.
• •Active viral, bacterial, or other infections or history of more than 2 infections requiring intravenous antibiotics within 12 months prior to signing the ICF.
• •Participants with corona virus disease 2019 (COVID-19) infection or who, in the judgment of the investigator, are at unacceptable risk of COVID-19 or its complications.
• •A documented positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) test within 2 weeks prior to randomization.
• •Received live (attenuated) vaccine within the 4 weeks prior to ICF signature.
• •Treated with any biologic B-cell-depleting therapy within 12 months or other B-cell targeting therapy \< 3 months before randomization.
• •Injectable corticosteroids (including intraarticular) or treatment with \> 10 mg/day dose oral prednisone or equivalent within 6 weeks prior to randomization (only for Population 1).
• •Treated with systemic corticosteroids for indications other than SS, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) for more than a total of 2 weeks within 24 weeks prior to screening visit (only for Population 1).
• •Received previous treatment with anti-CD40L compounds at any time before screening.
• •Pregnant or lactating or planning to get pregnant during the duration of the study.